

## Refine Search

### Search Results -

Terms	Documents
gehant.in.	2

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L12





### Search History

DATE: Friday, September 03, 2004    [Printable Copy](#)    [Create Case](#)

#### Set Name Query

side by side

#### Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L12</u>	gehant.in.	2	<u>L12</u>
<u>L11</u>	L9 and L10	30	<u>L11</u>
<u>L10</u>	L8 and (MgSO4)	460	<u>L10</u>
<u>L9</u>	L8 and PEI	619	<u>L9</u>
<u>L8</u>	L7 and solubility enhancer	48676	<u>L8</u>
<u>L7</u>	L6 and expanded bed	182082	<u>L7</u>
<u>L6</u>	L5 and column chromatography	191286	<u>L6</u>
<u>L5</u>	L4 and centrifugation	56761	<u>L5</u>
<u>L4</u>	L3 and (pH 4)	322544	<u>L4</u>
<u>L3</u>	L2 and acidic pH	322548	<u>L3</u>
<u>L2</u>	L1 and E. coli	50942	<u>L2</u>
<u>L1</u>	protein extract\$	517281	<u>L1</u>

END OF SEARCH HISTORY

## Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

### Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6213340 B1

L12: Entry 1 of 2

File: USPT

Apr 10, 2001

US-PAT-NO: 6213340

DOCUMENT-IDENTIFIER: US 6213340 B1

TITLE: Ice bucket for bottles, especially a champagne bucket

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Gehant</u> ; Andre Maurice Gilbert	Faucogney			FR

US-CL-CURRENT: 220/752; 220/770, 220/775

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 2. Document ID: US 4626204 A

L12: Entry 2 of 2

File: USPT

Dec 2, 1986

US-PAT-NO: 4626204

DOCUMENT-IDENTIFIER: US 4626204 A

TITLE: High-temperature hot-air generator

DATE-ISSUED: December 2, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Saint Julian; Raymond M.	Couvrot			FR
<u>Gehant</u> ; Philippe M.	Le Chesnay			FR
Bertrand; Ivan G.	Paris			FR
Folliet; Michel H.	Gargenville			FR

US-CL-CURRENT: 432/222; 110/265, 431/183, 431/186, 431/188, 431/190

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
gehant.in.	2

**Display Format:** [CIT](#)[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

### Search Results - Record(s) 1 through 10 of 30 returned.

☐ 1. Document ID: US 6784151 B2

L11: Entry 1 of 30

File: USPT

Aug 31, 2004

US-PAT-NO: 6784151

DOCUMENT-IDENTIFIER: US 6784151 B2

TITLE: Processes for making granular detergent composition having improved appearance and solubility

DATE-ISSUED: August 31, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capeci; Scott William	North Bend	OH		
Gabriel; Steven Matthew	Cincinnati	OH		
Jagannath; Girish	Higashinada-ku			JP
Donoghue; Scott John	Jesmond			GB
Morrison; Christopher Andrew	Brussels			BE

US-CL-CURRENT: 510/444; 23/313FB, 264/117, 264/140, 510/438

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 2. Document ID: US 6777539 B2

L11: Entry 2 of 30

File: USPT

Aug 17, 2004

US-PAT-NO: 6777539

DOCUMENT-IDENTIFIER: US 6777539 B2

TITLE: Soluble zalpha11 cytokine receptors

DATE-ISSUED: August 17, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sprecher; Cindy A.	Seattle	WA		
Novak; Julia E.	Bainbridge Island	WA		
West; James W.	Seattle	WA		
Presnell; Scott R.	Tacoma	WA		

Holly; Richard D.                      Seattle                      WA  
Nelson; Andrew J.                      Shoreline                      WA

US-CL-CURRENT: 530/350; 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MM	Draw
------	-------	----------	-------	--------	----------------	------	-----------	--------	----	------

☐ 3. Document ID: US 6770609 B1

L11: Entry 3 of 30

File: USPT

Aug 3, 2004

US-PAT-NO: 6770609

DOCUMENT-IDENTIFIER: US 6770609 B1

TITLE: Light reflecting particles

DATE-ISSUED: August 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morrison; Christopher Andrew	Cullercoats			GB

US-CL-CURRENT: 510/348; 510/440, 510/446

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MM	Draw
------	-------	----------	-------	--------	----------------	------	-----------	--------	----	------

☐ 4. Document ID: US 6743791 B2

L11: Entry 4 of 30

File: USPT

Jun 1, 2004

US-PAT-NO: 6743791

DOCUMENT-IDENTIFIER: US 6743791 B2

TITLE: Heterocyclic inhibitors of ERK2 and uses thereof

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cao; Jingrong	Newton	MA		
Green; Jeremy	Burlington	MA		
Hale; Michael	Bedford	MA		
Maltais; Francois	Tewksbury	MA		
Straub; Judy	Cambridge	MA		
Tang; Qing	Cambridge	MA		
Aronov; Alex	Watertown	MA		

US-CL-CURRENT: 514/235.8; 514/266.22, 514/275, 544/122, 544/284, 544/331

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 5. Document ID: US 6723523 B2

L11: Entry 5 of 30

File: USPT

Apr 20, 2004

US-PAT-NO: 6723523

DOCUMENT-IDENTIFIER: US 6723523 B2

TITLE: System and method for investigating the effect of chemical and other factors  
on cell movement

DATE-ISSUED: April 20, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lynes; Michael A.	Willington	CT		
Knecht; David A.	Storrs	CT		

US-CL-CURRENT: 435/7.21; 435/287.1, 435/288.4, 435/288.5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 6. Document ID: US 6692924 B2

L11: Entry 6 of 30

File: USPT

Feb 17, 2004

US-PAT-NO: 6692924

DOCUMENT-IDENTIFIER: US 6692924 B2

TITLE: Methods of using cytokine receptor zalph11 to detect its ligands

DATE-ISSUED: February 17, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Presnell; Scott R.	Tacoma	WA		
Conklin; Darrell C.	Seattle	WA		
Novak; Julia E.	Bainbridge Island	WA		
Hammond; Angela K.	Issaquah	WA		

US-CL-CURRENT: 435/7.1; 435/69.7, 435/7.2, 530/350, 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 7. Document ID: US 6683043 B1

L11: Entry 7 of 30

File: USPT

Jan 27, 2004

US-PAT-NO: 6683043

DOCUMENT-IDENTIFIER: US 6683043 B1

TITLE: Process for manufacturing effervescence components

DATE-ISSUED: January 27, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dovey; Anthony	Swarland			GB
Gray; Peter Gerard	Killingworth			GB
Baston; Gail Margaret	Whitley Bay			GB
Dyter; Zoe	Gosforth			GB
Driffield; Christopher Charles	High Heaton			GB
York; David William	Ponteland			GB

US-CL-CURRENT: 510/444; 510/446, 510/509, 510/513, 510/533

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 8. Document ID: US 6677147 B2

L11: Entry 8 of 30

File: USPT

Jan 13, 2004

US-PAT-NO: 6677147

DOCUMENT-IDENTIFIER: US 6677147 B2

TITLE: Pectate lyases

DATE-ISSUED: January 13, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andersen; Lene Nonboe	Allerod			DK
Schulein; Martin	late of Copenhagen			DK
Lange; Niels Erik Krebs	Raleigh	NC		
Bj.o slashed.rnvad; Mads Eskelund	Frederiksberg			DK
M.o slashed.ller; S.o slashed.ren	Holte			DK
Glad; Sanne O. Schroder	Ballerup			DK
Kauppinen; Markus Sakari	Copenhagen N			DK
Schnorr; Kirk	Copenhagen N			DK
Kongsbak; Lars	Holte			DK

US-CL-CURRENT: 435/232

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 9. Document ID: US 6635610 B1

L11: Entry 9 of 30

File: USPT

Oct 21, 2003

US-PAT-NO: 6635610

DOCUMENT-IDENTIFIER: US 6635610 B1

TITLE: Detergent granules

DATE-ISSUED: October 21, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tatsuno; Teruaki	Osaka			JP
Hartshorn; Richard Timonthy	Wylam			GB
Norwood; Kevin	Cincinnati	OH		
Mort, III; Paul R.	Cincinnati	OH		
Bohlen; David Scott	West Chester	OH		
Gabriel; Steven Matthew	Cincinnati	OH		
Katsuda; Rinko	Kobe			JP
Hidalgo; Noe Ongcoy	Higashinada-Kobe			JP

US-CL-CURRENT: [510/276](#); [510/352](#), [510/438](#), [510/446](#), [510/498](#), [510/509](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Abstract	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	----------

☐ 10. Document ID: US 6583098 B1

L11: Entry 10 of 30

File: USPT

Jun 24, 2003

US-PAT-NO: 6583098

DOCUMENT-IDENTIFIER: US 6583098 B1

TITLE: Detergent composition

DATE-ISSUED: June 24, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cassie; Leslie Hugh	Morpeth			GB

US-CL-CURRENT: [510/376](#); [510/444](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Abstract	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L9 and L10	30



**Display Format:**

[Previous Page](#)      [Next Page](#)      [Go to Doc#](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	6	May 27	Caplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS		JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004

=> file medline, uspatful, dgene, embase, wpids, fsta		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 09:40:33 ON 03 SEP 2004

FILE 'USPATFULL' ENTERED AT 09:40:33 ON 03 SEP 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 09:40:33 ON 03 SEP 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 09:40:33 ON 03 SEP 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 09:40:33 ON 03 SEP 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004  
COPYRIGHT (C) 2004 International Food Information Service

=> s protein extract?  
L1 14397 PROTEIN EXTRACT?

=> s l1 and E. coli cells  
5 FILES SEARCHED...  
L2 1187 L1 AND E. COLI CELLS

=> s protein extraction with acidic pH  
L3 0 PROTEIN EXTRACTION WITH ACIDIC PH

=> s l2 and acid  
L4 1172 L2 AND ACID

=> s l2 and acidic pH  
L5 28 L2 AND ACIDIC PH

=> s l5 and l4  
L6 28 L5 AND L4

=> s l6 and disrupt cells  
L7 0 L6 AND DISRUPT CELLS

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 28 USPATFULL on STN

TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184572 USPATFULL  
TITLE: Recombinant botulinum toxins having a soluble  
C-terminal portion of a heavy chain, an N-terminal  
portion of a heavy chain and a light chain  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine,  
CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	9089		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 28 USPATFULL on STN

TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:150994 USPATFULL  
TITLE: Recombinant botulinum toxins with a soluble C-terminal  
portion, an N-terminal portion and a light chain  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine,  
CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 40 Drawing Page(s)  
LINE COUNT: 16342  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 28 USPATFULL on STN

TI Process for **protein extraction**

AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64493 USPATFULL  
TITLE: Process for **protein extraction**  
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 28 USPATFULL on STN

TI Transmembrane proteins

AB The invention provides human transmembrane proteins (TMP) and polynucleotides which identify and encode TMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TMP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64491 USPATFULL  
TITLE: Transmembrane proteins  
INVENTOR(S): Warren, Bridget A, Encinitas, CA, UNITED STATES  
Xu, Yuming, Mountain View, CA, UNITED STATES  
Yue, Henry, Sunnyvale, CA, UNITED STATES  
Batra, Sajeev, Oakland, CA, UNITED STATES  
Burford, Neil, Durham, CT, UNITED STATES  
Gandhi, Ameena R, San Francisco, CA, UNITED STATES  
Chawla, Narinder K, Union City, CA, UNITED STATES  
Arvizu, Chandra S, San Jose, CA, UNITED STATES  
Tang, Y Tom, San Jose, CA, UNITED STATES  
Lu, Dyung Aina M, San Jose, CA, UNITED STATES  
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES

Baughn, Mariah R, San Leandro, CA, UNITED STATES  
 Lee, Ernestine A, Castro Valley, CA, UNITED STATES  
 Khan, Farrah A, Glen View, IL, UNITED STATES  
 Nguyen, Danniel B, San Jose, CA, UNITED STATES  
 Azimzai, Yalda, Oakland, CA, UNITED STATES  
 Yao, Monique G, Carmel, IN, UNITED STATES  
 Lal, Preeti G, Santa Clara, CA, UNITED STATES  
 Thangavelu, Kavitha, Mountain View, CA, UNITED STATES  
 Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
 Tran, Bao, Santa Clara, CA, UNITED STATES  
 Ding, Li, Creve Coeur, MI, UNITED STATES  
 Au-Young, Janice K, Brisbane, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049010	A1	20040311
APPLICATION INFO.:	US 2003-415188	A1	20030423 (10)
	WO 2001-US49670		20011026
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	89		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7985		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 28 USPATFULL on STN  
 TI Soluble recombinant botulinum toxins  
 AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2003:311862 USPATFULL  
 TITLE: Soluble recombinant botulinum toxins  
 INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
 PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219457	A1	20031127
APPLICATION INFO.:	US 2002-271012	A1	20021015 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16361		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 28 USPATFULL on STN

TI Soluble recombinant botulinum toxin proteins

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306036 USPATFULL

TITLE: Soluble recombinant botulinum toxin proteins

INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES

Thalley, Bruce S., Madison, WI, UNITED STATES

PATENT ASSIGNEE(S): Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
-----			
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16347		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 28 USPATFULL on STN

TI Methods and reagents for decreasing clinical reaction to allergy

AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:288222 USPATFULL

TITLE: Methods and reagents for decreasing clinical reaction

INVENTOR(S): to allergy  
 Caplan, Michael J., Woodbridge, CT, UNITED STATES  
 Sosin, Howard B., Fairfield, CT, UNITED STATES  
 Sampson, Hugh, Larchmont, NY, UNITED STATES  
 Bannon, Gary A., Wentzville, MO, UNITED STATES  
 Burks, A. Wesley, JR., Little Rock, AR, UNITED STATES  
 Cockrell, Gael, Cabot, AR, UNITED STATES  
 Compadre, Cesar M., Little Rock, AR, UNITED STATES  
 Connaughton, Cathie, Conway, AR, UNITED STATES  
 Helm, Ricki M., Little Rock, AR, UNITED STATES  
 King, Nina E., Mason, OH, UNITED STATES  
 Kopper, Randall A., Conway, AR, UNITED STATES  
 Maleki, Soheila J., New Orleans, LA, UNITED STATES  
 Rabjohn, Patrick A., Little Rock, AR, UNITED STATES  
 Shin, David S., San Diego, CA, UNITED STATES  
 Stanley, J. Steven, North Little Rock, AR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202980	A1	20031030
APPLICATION INFO.:	US 2002-100303	A1	20020318 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-494096, filed on 28 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-267719, filed on 11 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248674, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248673, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-241101, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-240557, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-141220, filed on 27 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-106872, filed on 29 Jun 1998, GRANTED, Pat. No. US 6486311 Continuation-in-part of Ser. No. US 1998-191593, filed on 13 Nov 1998, PENDING Continuation of Ser. No. US 1996-717933, filed on 23 Sep 1996, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122450P	19990302 (60)
	US 1999-122452P	19990302 (60)
	US 1999-122560P	19990302 (60)
	US 1999-122565P	19990302 (60)
	US 1999-122566P	19990302 (60)
	US 1998-74633P	19980213 (60)
	US 1998-74624P	19980213 (60)
	US 1998-74590P	19980213 (60)
	US 1998-73283P	19980131 (60)
	US 1995-9455P	19951229 (60)
	US 2001-276822P	20010316 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109  
 NUMBER OF CLAIMS: 40  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 99 Drawing Page(s)  
 LINE COUNT: 6600  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 28 USPATFULL on STN  
 TI Method for cleavage of fusion proteins



AB An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:238005 USPATFULL  
TITLE: Method for cleavage of fusion proteins  
INVENTOR(S): Van Rooijen, Gijs, Calgary, CANADA  
Alcantara, Joenel, Calgary, CANADA  
Moloney, Maurice M., Calgary, CANADA  
PATENT ASSIGNEE(S): SemBioSys Genetics Inc., Calgary, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166162	A1	20030904
APPLICATION INFO.:	US 2002-322746	A1	20021219 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-402488, filed on 16 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-CA398, filed on 23 Apr 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44254P	19970425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 28 USPATFULL on STN

TI Methods and compositions for production of recombinant peptides

AB This invention entails a method for solubilizing and recovering, in bioactive and isolated form with retained native state configuration, a target peptide from a host organism in which the heterologous polypeptide is present in insoluble form. Broadly this method comprises (i) disrupting the host cell to produce a lysate (ii) recovering lysate precipitate containing the polypeptide (iii) resuspending the lysate precipitate in a denaturant-free, non-buffered solubilization solution to produce a solubilization preparation that comprises both sodium hydroxide between about 8 and about 10 mM and the target peptide between about 1 and about 4 mg peptide per ml solubilization solution, wherein the resultant solubilization preparation has a pH of between about 9 and about 11.2; (iv) recovering supernatant from the solubilization preparation containing non-denatured target peptide. Optionally, stabilizing compounds and detergents are employed. The invention further comprises isolated insoluble proteins in bioactive form and native state configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:237905 USPATFULL  
TITLE: Methods and compositions for production of recombinant peptides  
INVENTOR(S): Gonzalez-Villasenor, Lucia Irene, Baltimore, MD, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003166062 A1 20030904  
APPLICATION INFO.: US 2002-80919 A1 20020222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270839P	20010223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Thomas M Saunders, Brown Rudnick Berlack Israels LLP, 18th Floor, One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2054	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 10 OF 28 USPATFULL on STN

TI Vaccine and antitoxin for treatment and prevention of C. difficile disease

AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in avian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:234579 USPATFULL  
TITLE: Vaccine and antitoxin for treatment and prevention of C. difficile disease  
INVENTOR(S): Kink, John A., Madison, WI, United States  
Williams, James A., Lincoln, NE, United States  
PATENT ASSIGNEE(S): Promega Corporation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6613329	B1	20030902
APPLICATION INFO.:	US 1998-84517		19980526 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary		
ASSISTANT EXAMINER:	Turner, Sharon		
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 46 Drawing Page(s)		

LINE COUNT: 11913  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 28 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:134527 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092615	A1	20030515
APPLICATION INFO.:	US 2002-115928	A1	20020405 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764861, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)

US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)

US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 21689  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 28 USPATFULL on STN  
TI Hyaluronan synthase genes and expression thereof in bacillus hosts  
AB The present invention relates to a recombinant Bacillus host cell  
containing a recombinant vector including a nucleic acid  
segment having a coding region segment encoding enzymatically active  
hyaluronan synthase (HAS). The recombinant Bacillus host cell is  
utilized in a method for producing hyaluronic acid (HA).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:134033 USPATFULL

TITLE: Hyaluronan synthase genes and expression thereof in  
bacillus hosts  
INVENTOR(S): DeAngelis, Paul L., Edmond, OK, UNITED STATES  
Weigel, Paul H., Edmond, OK, UNITED STATES  
Kumari, Kshama, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092118	A1	20030515
APPLICATION INFO.:	US 2002-172527	A1	20020613 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)
	US 2001-297788P	20010613 (60)
	US 2001-297744P	20010613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114	
NUMBER OF CLAIMS:	308	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	4894	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 13 OF 28 USPATFULL on STN

TI Hyaluronan synthase gene and uses thereof

AB The present invention relates to a nucleic **acid** segment having  
a coding region segment encoding enzymatically active Streptococcus  
equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic  
**acid** segment in the preparation of recombinant cells which  
produce hyaluronate synthase and its hyaluronic **acid** product.  
Hyaluronate is also known as hyaluronic **acid** or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:120299 USPATFULL  
TITLE: Hyaluronan synthase gene and uses thereof  
INVENTOR(S): Weigel, Paul H., Edmond, OK, UNITED STATES  
Kumari, Kshama, Oklahoma City, OK, UNITED STATES  
DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082780	A1	20030501
APPLICATION INFO.:	US 2001-11771	A1	20011211 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-146893, filed on 3 Sep 1998, GRANTED, Pat. No. US 6455304 Continuation of Ser. No. US 1994-270581, filed on 1 Jul 1994, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114	

NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Page(s)  
LINE COUNT: 2904  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 28 USPATFULL on STN  
TI Hyaluronan synthase gene and uses thereof  
AB The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active Streptococcus equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic acid segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic acid product. Hyaluronate is also known as hyaluronic acid or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106310 USPATFULL  
TITLE: Hyaluronan synthase gene and uses thereof  
INVENTOR(S): Weigel, Paul H., Edmond, OK, UNITED STATES  
Kumari, Kshama, Oklahoma City, OK, UNITED STATES  
DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073221	A1	20030417
APPLICATION INFO.:	US 2001-11768	A1	20011211 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	2909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 28 USPATFULL on STN  
TI Apoptosis related polynucleotides, polypeptides, and antibodies  
AB The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:71447 USPATFULL  
TITLE: Apoptosis related polynucleotides, polypeptides, and antibodies  
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003049732 A1 20030313  
 APPLICATION INFO.: US 2001-13477 A1 20011213 (10)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-669445, filed on 25  
 Sep 2000, PENDING Continuation-in-part of Ser. No. WO  
 2000-US6642, filed on 15 Mar 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126018P	19990324 (60)
	US 1999-139638P	19990617 (60)
	US 1999-149449P	19990818 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 12594

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 28 USPATFULL on STN

TI Compositions and methods for treatment of neoplastic disease

AB The present invention comprises compositions and methods for treating a  
 tumor or neoplastic disease in a host, The methods employ conjugates  
 comprising superantigen polypeptides, nucleic acids with other  
 structures that preferentially bind to tumor cells and are capable of  
 inducing apoptosis. Also provided are superantigen-glycolipid conjugates  
 and vesicles that are loaded onto antigen presenting cells to activate  
 both T cells and NKT cells. Cell-based vaccines comprise tumor cells  
 engineered to express a superantigen along with glycolipids products  
 which, when expressed, render the cells capable of eliciting an  
 effective anti-tumor immune response in a mammal into which these cells  
 are introduced. Included among these compositions are tumor cells,  
 hybrid cells of tumor cells and accessory cells, preferably dendritic  
 cells. Also provided are tumoricidal T cells and NKT cells devoid of  
 inhibitory receptors or inhibitory signaling motifs which are  
 hyperresponsive to the the above compositions and lipid-based tumor  
 associated antigens that can be administered for adoptive immunotherapy  
 of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:315069 USPATFULL

TITLE: Compositions and methods for treatment of neoplastic  
 disease

INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177551	A1	20021128
APPLICATION INFO.:	US 2001-870759	A1	20010530 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208128P	20000531 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	17323	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L6 ANSWER 17 OF 28 USPATFULL on STN  
TI Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis  
AB The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active Streptococcus equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic acid segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic acid product. Hyaluronate is also known as hyaluronic acid or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:287626 USPATFULL  
TITLE: Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis  
INVENTOR(S): Weigel, Paul H., Edmond, OK, UNITED STATES  
Kumari, Kshama, Oklahoma City, OK, UNITED STATES  
DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160489	A1	20021031
APPLICATION INFO.:	US 2001-879959	A1	20010912 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1997-899040, filed on 23 Jul 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Dunlap, Coddling & Rogers, P.C., Suite 420, 9400 North Broadway, Oklahoma City, OK, 73114	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	2727	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 28 USPATFULL on STN  
TI Endonuclease compositions and methods of use  
AB Disclosed are methods for modulating apoptosis and altering programmed cell death events using novel Endo-SR gene compositions and the polypeptides encoded thereby. Also disclosed are methods for repairing DNA, modulating genetic recombination in a cell, and altering DNA rearrangement in a host cell. Also disclosed are methods for the design and isolation of peptidomimetics and other inhibitors of Endo-SR useful in the treatment of leukemias, lymphomas, and other cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:246537 USPATFULL  
TITLE: Endonuclease compositions and methods of use  
INVENTOR(S): Aguilera, Renato J., Culver City, CA, United States  
Lyon, Christopher J., Los Angeles, CA, United States  
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455250	B1	20020924
APPLICATION INFO.:	US 1998-210422		19981211 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-69205P 19971211 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Priebe, Scott D.  
ASSISTANT EXAMINER: Chen, Shin-Lin  
LEGAL REPRESENTATIVE: Mandel & Adriano  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 6414  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 28 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:165182 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002086811	A1	20020704	
	US 2003171252	A9	20030911	
APPLICATION INFO.:	US 2001-764861	A1	20010117	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-179065P	20000131	(60)
	US 2000-180628P	20000204	(60)
	US 2000-214886P	20000628	(60)
	US 2000-217487P	20000711	(60)
	US 2000-225758P	20000814	(60)
	US 2000-220963P	20000726	(60)
	US 2000-217496P	20000711	(60)
	US 2000-225447P	20000814	(60)
	US 2000-218290P	20000714	(60)
	US 2000-225757P	20000814	(60)
	US 2000-226868P	20000822	(60)
	US 2000-216647P	20000707	(60)
	US 2000-225267P	20000814	(60)
	US 2000-216880P	20000707	(60)
	US 2000-225270P	20000814	(60)
	US 2000-251869P	20001208	(60)
	US 2000-235834P	20000927	(60)
	US 2000-234274P	20000921	(60)
	US 2000-234223P	20000921	(60)
	US 2000-228924P	20000830	(60)
	US 2000-224518P	20000814	(60)

US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 22023  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 28 USPATFULL on STN  
TI Vaccine and antitoxin for the treatment of C. difficile disease  
AB The present invention provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are produced with portions of C. difficile Toxin A, or Toxin B, or both. These portions of Toxins A and B may be fusion proteins with at least one non-toxin protein sequence, and may also be soluble and substantially endotoxin-free. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2001:157798 USPATFULL  
TITLE: Vaccine and antitoxin for the treatment of C. difficile disease  
INVENTOR(S): Kink, John A., Madison, WI, United States  
Thalley, Bruce S., Madison, WI, United States  
Stafford, Douglas C., Madison, WI, United States  
PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6290960	B1	20010918
APPLICATION INFO.:	US 1997-915136		19970820 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-480604, filed on 7 Jun		

1995, now patented, Pat. No. US 5736139  
Continuation-in-part of Ser. No. US 1995-422711, filed  
on 14 Apr 1995, now abandoned Continuation-in-part of  
Ser. No. US 1995-405496, filed on 16 Mar 1995, now  
patented, Pat. No. US 5919665 Continuation-in-part of  
Ser. No. US 1994-329154, filed on 24 Oct 1994, now  
abandoned Continuation-in-part of Ser. No. US  
1993-161907, filed on 2 Dec 1993, now patented, Pat.  
No. US 5601823 Continuation-in-part of Ser. No. US  
1992-985321, filed on 4 Dec 1992 Continuation-in-part  
of Ser. No. US 1989-429791, filed on 31 Oct 1989, now  
patented, Pat. No. US 5196193

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Navarro, Albert  
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 55 Drawing Figure(s); 54 Drawing Page(s)  
LINE COUNT: 11041  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 28 USPATFULL on STN  
TI Methods for producing heterologous disulfide bond-containing  
polypeptides in bacterial cells  
AB Disclosed are methods and compositions for producing heterologous  
disulfide bond containing polypeptides in bacterial cells. In preferred  
embodiments the methods involve co-expression of a prokaryotic disulfide  
isomerase, such as DsbC or DsbG and a gene encoding a recombinant  
eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue  
plasminogen activator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:84056 USPATFULL  
TITLE: Methods for producing heterologous disulfide  
bond-containing polypeptides in bacterial cells  
INVENTOR(S): Georgiou, George, Austin, TX, United States  
Oiu, Ji, Austin, TX, United States  
Bessette, Paul, Austin, TX, United States  
Swartz, James, Menlo Park, CA, United States  
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,  
Austin, TX, United States (U.S. corporation)  
Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6083715		20000704
APPLICATION INFO.:	US 1997-871483		19970609 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Patterson, Jr., Charles L.		
ASSISTANT EXAMINER:	Tung, Peter P.		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	2915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 28 USPATFULL on STN  
TI Methods for producing soluble, biologically-active disulfide-bond  
containing eukaryotic proteins in bacterial cells  
AB Disclosed are methods of producing eukaryotic disulfide bond-containing

polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:21382 USPATFULL  
 TITLE: Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells  
 INVENTOR(S): Georgiou, George, Austin, TX, United States  
 Ostermeier, Marc, State College, PA, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027888		20000222
APPLICATION INFO.:	US 1997-834516		19970404 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14950P	19960405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Guzo, David	
ASSISTANT EXAMINER:	Sandals, William	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	4029	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 28 USPATFULL on STN

TI MN gene and protein

AB Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. The MN protein has been determined to be the first tumor-associated carbonic anhydrase isoenzyme that has been described. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression, e.g., immunoassays and nucleic acid hybridization assays, are provided. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, conjugated or unconjugated to cytotoxic agents, and the use of MN antisense nucleic acids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:21381 USPATFULL  
 TITLE: MN gene and protein  
 INVENTOR(S): Zavada, Jan, Prague, Czech Republic  
 Pastorekova, Silvia, Bratislava, Slovakia  
 Pastorek, Jaromir, Bratislava, Slovakia  
 PATENT ASSIGNEE(S): Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027887		20000222

APPLICATION INFO.: US 1997-787739 19970124 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-485049, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-486756, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-477504, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-481658, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-485862, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-485863, filed on 7 Jun 1995 And Ser. No. US 1995-487077, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-260190, filed on 15 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-177093, filed on 30 Dec 1993 which is a continuation-in-part of Ser. No. US 1992-964589, filed on 21 Oct 1992, now patented, Pat. No. US 5387676, issued on 7 Feb 1995

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Jones, W. Gary  
 ASSISTANT EXAMINER: Whisenant, Ethan  
 LEGAL REPRESENTATIVE: Lauder, Leona L., Morgenstern, Arthur S.  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Figure(s); 14 Drawing Page(s)  
 LINE COUNT: 5256  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 28 USPATFULL on STN  
 TI Vaccine for clostridium botulinum neurotoxin  
 AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:75522 USPATFULL  
 TITLE: Vaccine for clostridium botulinum neurotoxin  
 INVENTOR(S): Williams, James A., Madison, WI, United States  
 PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919665		19990706
APPLICATION INFO.:	US 1995-405496		19950316 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-329154, filed on 25 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23 Mar 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Eisenschenk, Frank C.		
ASSISTANT EXAMINER:	Rabin, Evelyn		
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 29 Drawing Page(s)		

LINE COUNT: 9164  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 28 USPATFULL on STN  
TI Therapeutic fragments of von Willebrand factor  
AB Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an **acidic pH**; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:154386 USPATFULL  
TITLE: Therapeutic fragments of von Willebrand factor  
INVENTOR(S): Farb, David L., Chalfont, PA, United States  
Hrinda, Michael E., Gwynedd Valley, PA, United States  
Lee, Ted C. K., Lansdale, PA, United States  
Prior, Christopher P., Wayne, PA, United States  
Weber, David, Norristown, PA, United States  
PATENT ASSIGNEE(S): Centeon L.L.C., King of Prussia, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5847086		19981208
APPLICATION INFO.:	US 1995-487445		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-198849, filed on 18 Feb 1994, now patented, Pat. No. US 5539086 which is a continuation of Ser. No. US 1991-717942, filed on 20 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1680		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 28 USPATFULL on STN  
TI Treatment of Clostridium difficile induced disease  
AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in arian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:36359 USPATFULL  
TITLE: Treatment of Clostridium difficile induced disease  
INVENTOR(S): Kink, John A., Madison, WI, United States  
Thalley, Bruce S., Madison, WI, United States  
Stafford, Douglas C., Madison, WI, United States  
Firca, Joseph R., Vernon Hills, IL, United States  
Padhye, Nisha V., Madison, WI, United States  
PATENT ASSIGNEE(S): Ochidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5736139		19980407
APPLICATION INFO.:	US 1995-480604		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-422711, filed on 14 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23 Mar 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Eisenschenk, Frank C.		
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	55 Drawing Figure(s); 53 Drawing Page(s)		
LINE COUNT:	11770		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 28 USPATFULL on STN

TI Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays

AB Isolated and/or recombinant nucleic acids encoding mycobacterial seryl-tRNA synthetase have been characterized. Recombinant DNA constructs and vectors having a sequence which encodes mycobacterial seryl-tRNA synthetase have been made, and can be used for the construction of tester strains as well as for the production of isolated and/or recombinant seryl-tRNA synthetases. These enzymes or portions thereof are useful in the biochemical separation of serine and quantification of serine or ATP, and for producing antibodies useful in the purification and study of the enzyme, for example. Host cells and methods useful for producing recombinant mycobacterial seryl-tRNA synthetases are described, as are tester strains, which are cells engineered to rely on the function of the tRNA synthetase encoded by an introduced cloned gene. Tester strains can be used to identify inhibitors of the essential tRNA synthetase enzyme encoded by the introduced cloned gene, and thus provide a means to assess the antimicrobial effect and specificity of the inhibitor without employing slow-growing, pathogenic strains of mycobacteria, such as Mycobacterium tuberculosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:70912 USPATFULL  
TITLE: Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays  
INVENTOR(S): Martinis, Susan A., Newton, MA, United States



PATENT ASSIGNEE(S): Zhang, Jiansu, Cambridge, MA, United States  
Schimmel, Paul R., Cambridge, MA, United States  
Cubist Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656470		19970812
APPLICATION INFO.:	US 1994-305172		19940913 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2043		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 28 USPATFULL on STN  
TI Therapeutic fragments of von Willebrand factor  
AB An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:

- (A) providing an aqueous solution of the fragment and denaturant;
- (B) purifying the solution of fragment and denaturant under conditions which promote conversion of aggregated forms of the fragment to the dimeric and/or monomeric forms thereof to provide purified fragment;
- (C) separating the dissolved, purified fragment from the denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said purified fragment, thereby forming an aqueous solution of fragment which is substantially free of aggregate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:65675 USPATFULL  
TITLE: Therapeutic fragments of von Willebrand factor  
INVENTOR(S): Farb, David L., Chalfont, PA, United States  
Hrinda, Michael E., Gwynedd Valley, PA, United States  
Lee, Ted C. K., Lansdale, PA, United States  
Prior, Christopher P., Wayne, PA, United States  
PATENT ASSIGNEE(S): Rh one-Poulenc Rorer Pharmaceuticals Inc.,  
Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5539086		19960723
APPLICATION INFO.:	US 1994-198849		19940218 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-717942, filed on 20 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1406		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33  
ON 03 SEP 2004

L1 14397 S PROTEIN EXTRACT?  
L2 1187 S L1 AND E. COLI CELLS  
L3 0 S PROTEIN EXTRACTION WITH ACIDIC PH  
L4 1172 S L2 AND ACID  
L5 28 S L2 AND ACIDIC PH  
L6 28 S L5 AND L4  
L7 0 S L6 AND DISRUPT CELLS

=> s l6 and centrifugation

L8 27 L6 AND CENTRIFUGATION

=> s l8 and expanded bed chromatography

L9 1 L8 AND EXPANDED BED CHROMATOGRAPHY

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 1 USPATFULL on STN

TI Process for **protein extraction**

AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64493 USPATFULL

TITLE: Process for **protein extraction**

INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33  
ON 03 SEP 2004

L1 14397 S PROTEIN EXTRACT?  
L2 1187 S L1 AND E. COLI CELLS  
L3 0 S PROTEIN EXTRACTION WITH ACIDIC PH  
L4 1172 S L2 AND ACID  
L5 28 S L2 AND ACIDIC PH  
L6 28 S L5 AND L4  
L7 0 S L6 AND DISRUPT CELLS  
L8 27 S L6 AND CENTRIFUGATION  
L9 1 S L8 AND EXPANDED BED CHROMATOGRAPHY

=> s solubility enhancer

L10 261 SOLUBILITY ENHANCER

=> s l10 and (MgSO4)

L11 2 L10 AND (MGSO4)

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 2 USPATFULL on STN

TI Synthesis of epothilones, intermediates thereto and analogues thereof

AB The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:113071 USPATFULL

TITLE: Synthesis of epothilones, intermediates thereto and analogues thereof

INVENTOR(S): Danishefsky, Samuel J., Englewood, NJ, UNITED STATES  
Stachel, Shawn J., Perkasie, PA, UNITED STATES  
Lee, Chul Bom, Princeton, NJ, UNITED STATES  
Chappell, Mark D., Noblesville, IN, UNITED STATES  
Wu, Zhicai, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058817	A1	20020516
APPLICATION INFO.:	US 2001-796959	A1	20010301 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185968P	20000301 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	47 Drawing Page(s)	
LINE COUNT:	5609	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 2 USPATFULL on STN

TI Synthesis of epothilones, intermediates thereto and analogues thereof

AB The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:112551 USPATFULL

TITLE: Synthesis of epothilones, intermediates thereto and analogues thereof

INVENTOR(S): Danishefsky, Samuel J., Englewood, NJ, UNITED STATES  
Stachel, Shawn J., Perkasi, PA, UNITED STATES  
Lee, Chul Bom, Princeton, NJ, UNITED STATES  
Chappell, Mark D., Noblesville, IN, UNITED STATES  
Chou, Ting-Chao, Paramus, NJ, UNITED STATES  
Wu, Zhicai, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058286	A1	20020516
APPLICATION INFO.:	US 2001-797027	A1	20010301 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-257072, filed on 24 Feb 1999, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109		
NUMBER OF CLAIMS:	61		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Page(s)		
LINE COUNT:	6056		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

L1 14397 S PROTEIN EXTRACT?  
L2 1187 S L1 AND E. COLI CELLS  
L3 0 S PROTEIN EXTRACTION WITH ACIDIC PH  
L4 1172 S L2 AND ACID  
L5 28 S L2 AND ACIDIC PH  
L6 28 S L5 AND L4  
L7 0 S L6 AND DISRUPT CELLS  
L8 27 S L6 AND CENTRIFUGATION  
L9 1 S L8 AND EXPANDED BED CHROMATOGRAPHY  
L10 261 S SOLUBILITY ENHANCER  
L11 2 S L10 AND (MGSO4)

=> s l10 and l8

L12 1 L10 AND L8

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 1 USPATFULL on STN

TI Process for **protein extraction**

AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a **solubility enhancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64493 USPATFULL

TITLE: Process for **protein extraction**  
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

L1 14397 S PROTEIN EXTRACT?  
L2 1187 S L1 AND E. COLI CELLS  
L3 0 S PROTEIN EXTRACTION WITH ACIDIC PH  
L4 1172 S L2 AND ACID  
L5 28 S L2 AND ACIDIC PH  
L6 28 S L5 AND L4  
L7 0 S L6 AND DISRUPT CELLS  
L8 27 S L6 AND CENTRIFUGATION  
L9 1 S L8 AND EXPANDED BED CHROMATOGRAPHY  
L10 261 S SOLUBILITY ENHANCER  
L11 2 S L10 AND (MGSO4)  
L12 1 S L10 AND L8

=> s l8 and PEI

L13 6 L8 AND PEI

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 6 USPATFULL on STN

TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain  
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184572 USPATFULL

TITLE: Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	9089		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L13 ANSWER 2 OF 6 USPATFULL on STN

TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:150994 USPATFULL

TITLE: Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain

INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES

PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16342		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 6 USPATFULL on STN

TI Process for **protein extraction**

AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64493 USPATFULL

TITLE: Process for **protein extraction**

INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 6 USPATFULL on STN

TI Soluble recombinant botulinum toxins

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:311862 USPATFULL

TITLE: Soluble recombinant botulinum toxins

INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES

PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219457	A1	20031127
APPLICATION INFO.:	US 2002-271012	A1	20021015 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US		

5919665  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300,  
IRVINE, CA, 92618  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 40 Drawing Page(s)  
LINE COUNT: 16361  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 6 USPATFULL on STN

TI Soluble recombinant botulinum toxin proteins  
AB The present invention includes recombinant proteins derived from  
Clostridium botulinum toxins. In particular, soluble recombinant  
Clostridium botulinum type A, type B and type E toxin proteins are  
provided. Methods which allow for the isolation of recombinant proteins  
free of significant endotoxin contamination are provided. The soluble,  
endotoxin-free recombinant proteins are used as immunogens for the  
production of vaccines and antitoxins. These vaccines and antitoxins are  
useful in the treatment of humans and other animals at risk of  
intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306036 USPATFULL  
TITLE: Soluble recombinant botulinum toxin proteins  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
Thalley, Bruce S., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan, Inc., Allergan Botox Limited, Irvine, CA,  
92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16347		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 6 USPATFULL on STN

TI Compositions and methods for treatment of neoplastic disease  
AB The present invention comprises compositions and methods for treating a  
tumor or neoplastic disease in a host, The methods employ conjugates  
comprising superantigen polypeptides, nucleic acids with other  
structures that preferentially bind to tumor cells and are capable of  
inducing apoptosis. Also provided are superantigen-glycolipid conjugates  
and vesicles that are loaded onto antigen presenting cells to activate  
both T cells and NKT cells. Cell-based vaccines comprise tumor cells  
engineered to express a superantigen along with glycolipids products  
which, when expressed, render the cells capable of eliciting an  
effective anti-tumor immune response in a mammal into which these cells  
are introduced. Included among these compositions are tumor cells,  
hybrid cells of tumor cells and accessory cells, preferably dendritic  
cells. Also provided are tumoricidal T cells and NKT cells devoid of



inhibitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:315069 USPATFULL

TITLE: Compositions and methods for treatment of neoplastic disease

INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177551	A1	20021128
APPLICATION INFO.:	US 2001-870759	A1	20010530 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208128P	20000531 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	17323	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

L1 14397 S PROTEIN EXTRACT?  
L2 1187 S L1 AND E. COLI CELLS  
L3 0 S PROTEIN EXTRACTION WITH ACIDIC PH  
L4 1172 S L2 AND ACID  
L5 28 S L2 AND ACIDIC PH  
L6 28 S L5 AND L4  
L7 0 S L6 AND DISRUPT CELLS  
L8 27 S L6 AND CENTRIFUGATION  
L9 1 S L8 AND EXPANDED BED CHROMATOGRAPHY  
L10 261 S SOLUBILITY ENHANCER  
L11 2 S L10 AND (MGSO4)  
L12 1 S L10 AND L8  
L13 6 S L8 AND PEI

=> d l8 ti abs ibib 1-10

L8 ANSWER 1 OF 27 USPATFULL on STN

TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain  
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184572 USPATFULL  
TITLE: Recombinant botulinum toxins having a soluble  
C-terminal portion of a heavy chain, an N-terminal  
portion of a heavy chain and a light chain  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine,  
CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	9089		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 27 USPATFULL on STN

TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:150994 USPATFULL  
TITLE: Recombinant botulinum toxins with a soluble C-terminal  
portion, an N-terminal portion and a light chain  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine,  
CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 40 Drawing Page(s)  
LINE COUNT: 16342  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 27 USPATFULL on STN  
TI Process for **protein extraction**  
AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64493 USPATFULL  
TITLE: Process for **protein extraction**  
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 27 USPATFULL on STN  
TI Soluble recombinant botulinum toxins  
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:311862 USPATFULL  
TITLE: Soluble recombinant botulinum toxins  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219457	A1	20031127
APPLICATION INFO.:	US 2002-271012	A1	20021015 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28		

Aug 1996, PENDING Continuation-in-part of Ser. No. US  
1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US  
5919665

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300,  
IRVINE, CA, 92618  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 40 Drawing Page(s)  
LINE COUNT: 16361  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 27 USPATFULL on STN

TI Soluble recombinant botulinum toxin proteins

AB The present invention includes recombinant proteins derived from  
Clostridium botulinum toxins. In particular, soluble recombinant  
Clostridium botulinum type A, type B and type E toxin proteins are  
provided. Methods which allow for the isolation of recombinant proteins  
free of significant endotoxin contamination are provided. The soluble,  
endotoxin-free recombinant proteins are used as immunogens for the  
production of vaccines and antitoxins. These vaccines and antitoxins are  
useful in the treatment of humans and other animals at risk of  
intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306036 USPATFULL  
TITLE: Soluble recombinant botulinum toxin proteins  
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES  
Thalley, Bruce S., Madison, WI, UNITED STATES  
PATENT ASSIGNEE(S): Allergan, Inc., Allergan Botox Limited, Irvine, CA,  
92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16347		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 6 OF 27 USPATFULL on STN

TI Methods and reagents for decreasing clinical reaction to allergy

AB It has been determined that allergens, which are characterized by both  
humoral (IgE) and cellular (T-cell) binding sites, can be modified to be  
less allergenic by modifying the IgE binding sites. The IgE binding  
sites can be converted to non-IgE binding sites by altering as little as  
a single amino acid within the protein, preferably a  
hydrophobic residue towards the center of the IgE epitope, to eliminate  
IgE binding. Additionally or alternatively a modified allergen with  
reduced IgE binding may be prepared by disrupting one or more of the  
disulfide bonds that are present in the natural allergen. The disulfide  
bonds may be disrupted chemically, e.g., by reduction and alkylation or  
by mutating one or more cysteine residues present in the primary amino

acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:288222 USPATFULL

TITLE: Methods and reagents for decreasing clinical reaction to allergy

INVENTOR(S): Caplan, Michael J., Woodbridge, CT, UNITED STATES  
 Sosin, Howard B., Fairfield, CT, UNITED STATES  
 Sampson, Hugh, Larchmont, NY, UNITED STATES  
 Bannon, Gary A., Wentzville, MO, UNITED STATES  
 Burks, A. Wesley, JR., Little Rock, AR, UNITED STATES  
 Cockrell, Gael, Cabot, AR, UNITED STATES  
 Compadre, Cesar M., Little Rock, AR, UNITED STATES  
 Connaughton, Cathie, Conway, AR, UNITED STATES  
 Helm, Ricki M., Little Rock, AR, UNITED STATES  
 King, Nina E., Mason, OH, UNITED STATES  
 Kopper, Randall A., Conway, AR, UNITED STATES  
 Maleki, Soheila J., New Orleans, LA, UNITED STATES  
 Rabjohn, Patrick A., Little Rock, AR, UNITED STATES  
 Shin, David S., San Diego, CA, UNITED STATES  
 Stanley, J. Steven, North Little Rock, AR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202980	A1	20031030
APPLICATION INFO.:	US 2002-100303	A1	20020318 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-494096, filed on 28 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-267719, filed on 11 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248674, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248673, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-241101, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-240557, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-141220, filed on 27 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-106872, filed on 29 Jun 1998, GRANTED, Pat. No. US 6486311 Continuation-in-part of Ser. No. US 1998-191593, filed on 13 Nov 1998, PENDING Continuation of Ser. No. US 1996-717933, filed on 23 Sep 1996, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122450P	19990302 (60)
	US 1999-122452P	19990302 (60)
	US 1999-122560P	19990302 (60)
	US 1999-122565P	19990302 (60)
	US 1999-122566P	19990302 (60)
	US 1998-74633P	19980213 (60)
	US 1998-74624P	19980213 (60)
	US 1998-74590P	19980213 (60)
	US 1998-73283P	19980131 (60)
	US 1995-9455P	19951229 (60)

US 2001-276822P 20010316 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State  
Street, Boston, MA, 02109  
NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 99 Drawing Page(s)  
LINE COUNT: 6600  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 27 USPATFULL on STN

TI Method for cleavage of fusion proteins

AB An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:238005 USPATFULL  
TITLE: Method for cleavage of fusion proteins  
INVENTOR(S): Van Rooijen, Gijs, Calgary, CANADA  
Alcantara, Joenel, Calgary, CANADA  
Moloney, Maurice M., Calgary, CANADA  
PATENT ASSIGNEE(S): SemBioSys Genetics Inc., Calgary, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166162	A1	20030904
APPLICATION INFO.:	US 2002-322746	A1	20021219 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-402488, filed on 16 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-CA398, filed on 23 Apr 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44254P	19970425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 27 USPATFULL on STN

TI Methods and compositions for production of recombinant peptides

AB This invention entails a method for solubilizing and recovering, in bioactive and isolated form with retained native state configuration, a target peptide from a host organism in which the heterologous polypeptide is present in insoluble form. Broadly this method comprises (i) disrupting the host cell to produce a lysate (ii) recovering lysate precipitate containing the polypeptide (iii) resuspending the lysate precipitate in a denaturant-free, non-buffered solubilization solution to produce a solubilization preparation that comprises both sodium hydroxide between about 8 and about 10 mM and the target peptide between about 1 and about 4 mg peptide per ml solubilization solution, wherein the resultant solubilization preparation has a pH of between about 9 and about 11.2; (iv) recovering supernatant from the solubilization preparation containing non-denatured target peptide. Optionally,

stabilizing compounds and detergents are employed. The invention further comprises isolated insoluble proteins in bioactive form and native state configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:237905 USPATFULL  
TITLE: Methods and compositions for production of recombinant peptides  
INVENTOR(S): Gonzalez-Villasenor, Lucia Irene, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166062	A1	20030904
APPLICATION INFO.:	US 2002-80919	A1	20020222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270839P	20010223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Thomas M Saunders, Brown Rudnick Berlack Israels LLP, 18th Floor, One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2054	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 27 USPATFULL on STN

TI Vaccine and antitoxin for treatment and prevention of C. difficile disease

AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in avian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:234579 USPATFULL  
TITLE: Vaccine and antitoxin for treatment and prevention of C. difficile disease  
INVENTOR(S): Kink, John A., Madison, WI, United States  
Williams, James A., Lincoln, NE, United States  
PATENT ASSIGNEE(S): Promega Corporation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6613329	B1	20030902
APPLICATION INFO.:	US 1998-84517		19980526 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed		

on 2 Dec 1993, now patented, Pat. No. US 5601823  
Continuation-in-part of Ser. No. US 1992-985321, filed  
on 4 Dec 1992 Continuation-in-part of Ser. No. US  
1989-429791, filed on 31 Oct 1989, now patented, Pat.  
No. US 5196193

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Kunz, Gary  
ASSISTANT EXAMINER: Turner, Sharon  
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP  
NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 46 Drawing Page(s)  
LINE COUNT: 11913  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 27 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically,  
isolated nucleic acid molecules are provided encoding novel  
polypeptides. Novel polypeptides and antibodies that bind to these  
polypeptides are provided. Also provided are vectors, host cells, and  
recombinant and synthetic methods for producing human polynucleotides  
and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating,  
preventing and/or prognosing disorders related to these novel  
polypeptides. The invention further relates to screening methods for  
identifying agonists and antagonists of polynucleotides and polypeptides  
of the invention. The present invention further relates to methods  
and/or compositions for inhibiting or enhancing the production and  
function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:134527 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092615	A1	20030515
APPLICATION INFO.:	US 2002-115928	A1	20020405 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764861, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)